Fewer ovulatory cycles, potentially resulting from longer oral contraceptive pill use, was associated with healthy fetal karyotypes among patients of advanced reproductive age.
The International Journal of Gynecology and Obstetrics regrets that, in the above article, an error appeared in the Results section of the Abstract;Instead of "lower estimated ovulation number," "higher estimated ovulation number" should be written. The corrected sentence appears as follows:Shorter mean length of oral contraceptive pill use before trisomic pregnancy (P<0.001) and a higher estimated ovulation number (P=0.012) were identified among patients with pregnancies with fetal trisomies.The International Journal of Gynecology and Obstetrics would like to apologize for any inconvenience caused.
A paroxysmalis nocturnalis haemoglobinuria igen ritka hematológiai betegség. Várandósság alatt különösen nagy kockázatot jelent, mind az anyára, mind a magzatra nézve. A betegségben szenvedőknél a terhesség sokáig ellenjavallt volt a magas kockázat miatt. Az utóbbi időben az eculizumab monoklonális antitest alkalmazása mellett a szövődmé-nyek csökkentésével lehetővé vált a terhességek biztonságosabb kiviselése. A betegséggel szövődött várandósságok esetén leggyakrabban thromboemboliás szövődmények fordulnak elő, a várandósság alatt folyamatos véralvadásgátló kezelés javasolt. Az ismertetett esetben az 5 éve ismert paroxysmalis nocturnalis haemoglobinuriában szenvedő beteg 29 éves korában esett teherbe először. A terhessége 11. hetében sinusthrombosis alakult ki, amelyből szövődmény-mentesen gyógyult. Ezt követően, eculizumab védelmében terhessége és szülése is szövődménymentes volt. A szakirodalomban nagyon kevés eset áll rendelkezésre a paroxysmalis nocturnalis haemoglobinuriával szövődött várandós-ságokat tekintve, de az utóbbi időben a kezelésében alkalmazott eculizumab várandósság alatti alkalmazhatóságával több sikeres terhességet mutattak be. Orv. Hetil., 2016, 157(23), 916-918.
Introduction
In 2008, Hultén et al hypothesized that maternal ovarian trisomy 21 mosaicism might be the primary causative factor for fetal Down syndrome. We hypothesize that this theory can be extended to trisomy 13.
Material and methods
We collected fetal ovarian tissue from seven female fetuses between 16 and 23 gestational weeks, following the termination of the pregnancy for non‐genetic reasons. All procedures were performed with informed consent and ethical approval from the local ethics committee. We used touch preparation techniques from fetal ovarian tissues and an anti‐stromal antigen 3 antibody against the meiosis‐specific stromal antigen 3 protein to differentiate between germ cells, ovarian stromal cells and the cells entering their first meiotic prophase. We used fluorescence in situ hybridization analysis to determine chromosome 13 numbers in each cell.
Results
We were able to detect a proportion of trisomy 13 cells in all cases. The average incidence of trisomy 13 cells was 2.04% in stromal antigen 3‐positive and 0.91% in the stromal antigen 3‐negative cells. The number of the trisomic cells increased significantly with gestational age (for stromal antigen 3‐positive cells r = 0.93, P = 0.0038, for stromal antigen 3‐negative cells r = 0.85, P = 0.0071).
Conclusions
This study indicates that besides trisomy 21, the Oocyte Mosaicism Selection model could be extended to trisomy 13 as well. The crucial factor for trisomy 13 seems to be the pre‐meiotic/mitotic trisomy 13 mosaicism, leading to a so‐called secondary meiotic nondisjunction of those oocytes having three copies of chromosome 13.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.